Enhanced drug delivery using sonoactivatable liposomes with membrane-embedded porphyrins
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Small molecules that interfere with nucleic acid are widely used in chemotherapy, however, improved delivery approaches are required to improve anti‐tumor outcomes. Here, we present the development of an ultrasound‐activatable porphyrin‐phospholipid‐liposome (pp‐lipo) that responds to low intensity focused ultrasound (LIFU) for sonodynamic therapy (SDT). The pp‐lipo is constructed by incorporating a small proportion of porphyrin (pyropheophorbide) conjugated lipid into a liposome formulation. This enables sonosensitization‐induced lipid oxidation and efficient disruption of liposomes to release loaded doxorubicin (Dox). This results in increased Dox nuclear subcellular location and cytotoxicity in cancer cells in vitro upon pp‐lipo exposure to LIFU. Following intravenous administration, LIFU enhanced deposition of Dox within tumor tissue, suppressed tumor growth, and also increased porphyrin near infrared tumor fluorescence. Thus, pp‐lipo is a versatile carrier that can be extended to many ultrasound‐controllable drug delivery applications. Graphical abstract Figure. No caption available. HighlightsPorphyrin‐lipid conferred liposomes with ultrasound‐responsive properties.Drug release from pp‐lipo was spatiotemporally controlled by ultrasound exposure.Ultrasound facilitated pp‐lipo imaging‐guided deep penetration of cargos.Dox‐pp‐lipo benefited from the synergy of sonodynamic therapy and chemotherapy.Pp‐lipo is versatile and can be extended to many ultrasound‐controllable deliveries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Haran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934
Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility.
Schroeder, A., Avnir, Y., Weisman, S., Najajreh, Y., Gabizon, A., Talmon, Y., Kost, J., & Barenholz, Y. (2007) · Langmuir · doi:10.1021/la0631668 · Cited by 239
Current status and future perspectives of sonodynamic therapy in glioma treatment.
Wang, X., Jia, Y., Wang, P., Liu, Q., & Zheng, H. (2017) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2017.02.020 · Cited by 86
Self-citation
Cited by
Porphyrin‐Based Metal–Organic Frameworks for Biomedical Applications
Chen, J., Zhu, Y., & Kaskel, S. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.201909880 · Cited by 597
Recent advancements in liposome technology
Filipczak, N., Pan, J., Yalamarty, S. S. K., & Torchilin, V. P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.022 · Cited by 592
Ultrasound‐Activated Sensitizers and Applications
Lin, X., Song, J., Chen, X., & Yang, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201906823 · Cited by 501
Gong, Z., & Dai, Z. (2021) · Advanced Science · doi:10.1002/advs.202002178 · Cited by 320
Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery
Almeida, B., Nag, O. K., Rogers, K. E., & Delehanty, J. B. (2020) · Molecules · doi:10.3390/molecules25235672 · Cited by 298
Metadata
- Authors
- Wang, X., Yan, F., Liu, X., Wang, P., Shao, S., Sun, Y., Sheng, Z., Liu, Q., Lovell, J. F., & Zheng, H.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 286
- Pages
- 358-368
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2887957636
- Cited by
- 100
- References
- 6
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.